Banking on speedy domestic clinical progress and low costs, Chinese developers of innovative drugs for rare diseases are calling time on the rarity of their go-global breakthroughs.
Key Takeaways
-
Chinese players in the rare disease space are venturing out of their home turf to advance assets into clinical studies worldwide, especially in the US.
-
Rapid progress in domestic clinical trials, together with the relatively low cost of clinical development and manufacturing at home, are playing into their advantages in the global push
Over the past few years, while Chinese-made novel drugs for various cancers have successfully landed in major international markets, including the US, products for rare disorders have yet to step onto the world stage
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?